Compare Biocon with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SUN PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SUN PHARMA BIOCON /
SUN PHARMA
 
P/E (TTM) x 31.3 133.7 23.4% View Chart
P/BV x 4.0 3.1 129.3% View Chart
Dividend Yield % 0.2 0.7 35.8%  

Financials

 BIOCON    SUN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
SUN PHARMA
Mar-20
BIOCON /
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs707484 146.1%   
Low Rs554315 175.7%   
Sales per share (Unadj.) Rs91.9136.9 67.2%  
Earnings per share (Unadj.) Rs16.717.5 95.8%  
Cash flow per share (Unadj.) Rs24.226.0 93.0%  
Dividends per share (Unadj.) Rs1.004.00 25.0%  
Dividend yield (eoy) %0.21.0 15.8%  
Book value per share (Unadj.) Rs101.6188.7 53.9%  
Shares outstanding (eoy) m600.002,399.26 25.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.92.9 235.0%   
Avg P/E ratio x37.722.9 164.8%  
P/CF ratio (eoy) x26.115.4 169.7%  
Price / Book Value ratio x6.22.1 292.9%  
Dividend payout %6.022.9 26.1%   
Avg Mkt Cap Rs m378,330958,864 39.5%   
No. of employees `0006.117.8 34.5%   
Total wages/salary Rs m11,65363,624 18.3%   
Avg. sales/employee Rs Th8,994.318,490.6 48.6%   
Avg. wages/employee Rs Th1,900.73,582.6 53.1%   
Avg. net profit/employee Rs Th1,635.32,357.6 69.4%   
INCOME DATA
Net Sales Rs m55,144328,375 16.8%  
Other income Rs m1,4446,360 22.7%   
Total revenues Rs m56,588334,735 16.9%   
Gross profit Rs m15,88369,898 22.7%  
Depreciation Rs m4,47820,528 21.8%   
Interest Rs m7093,027 23.4%   
Profit before tax Rs m12,14052,702 23.0%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m2,1238,228 25.8%   
Profit after tax Rs m10,02641,868 23.9%  
Gross profit margin %28.821.3 135.3%  
Effective tax rate %17.515.6 112.0%   
Net profit margin %18.212.8 142.6%  
BALANCE SHEET DATA
Current assets Rs m48,228316,542 15.2%   
Current liabilities Rs m30,376157,064 19.3%   
Net working cap to sales %32.448.6 66.7%  
Current ratio x1.62.0 78.8%  
Inventory Days Days6888 78.0%  
Debtors Days Days86105 81.7%  
Net fixed assets Rs m64,130243,102 26.4%   
Share capital Rs m3,0002,399 125.0%   
"Free" reserves Rs m57,980450,245 12.9%   
Net worth Rs m60,980452,645 13.5%   
Long term debt Rs m15,76620,289 77.7%   
Total assets Rs m121,924682,525 17.9%  
Interest coverage x18.118.4 98.4%   
Debt to equity ratio x0.30 576.8%  
Sales to assets ratio x0.50.5 94.0%   
Return on assets %8.86.6 133.9%  
Return on equity %16.49.2 177.8%  
Return on capital %16.811.2 149.2%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50674,219 20.9%   
Fx outflow Rs m10,39927,964 37.2%   
Net fx Rs m5,10746,255 11.0%   
CASH FLOW
From Operations Rs m11,54665,548 17.6%  
From Investments Rs m-7,138-25,888 27.6%  
From Financial Activity Rs m-2,417-57,151 4.2%  
Net Cashflow Rs m2,103-13,857 -15.2%  

Share Holding

Indian Promoters % 40.4 63.7 63.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.1 163.7%  
FIIs % 10.7 23.0 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.3 239.8%  
Shareholders   109,995 133,026 82.7%  
Pledged promoter(s) holding % 0.0 0.5 7.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   VENUS REMEDIES  ORCHID PHARMA  PFIZER  J.B.CHEMICALS  SHASUN PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 101 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.

Related Views on News

BIOCON Share Price Down by 10%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 10% and its current market price is Rs 424. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are AUROBINDO PHARMA (up 1.7%) and FORTIS HEALTHCARE (up 0.9%). The top losers is BIOCON (down 10.1%).

SRF Share Price Down by 5%; BSE 500 Index Up 0.3% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

SRF share price is trading down by 5% and its current market price is Rs 5,715. The BSE 500 is up by 0.3%. The top gainers in the BSE 500 Index are JK TYRE & IND (up 14.5%) and CYIENT (up 11.1%). The top losers are SRF (down 5.1%) and BIOCON (down 8.7%).

BIOCON Share Price Down by 6%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 6% and its current market price is Rs 424. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are PROCTER & GAMBLE HEALTH (up 2.6%) and JUBILANT LIFE SCIENCES (up 1.5%). The top losers is BIOCON (down 6.1%).

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 22, 2021 02:18 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS